
    
      This is a multicenter, open-label, Phase Ia/b dose escalation study of safety,
      pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to
      determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or
      Non-Hodgkin's Lymphoma patients. This is to be followed by a cohort expansion phase at the
      MTD or recommended oral dose.
    
  